InVivoMab anti-mouse Thy1 (CD90)

Kein Verkauf an Patienten, Ärzte, Apotheken oder Privatpersonen! Mehr erfahren

Hersteller Bio X Cell
Typ Antibody Monoclonal
Specific against Mouse
Clon T24/31
Isotype IgG2b
Applikationen in vivo
Menge 50mg
Host Rat
ArtNr BE0212-50MG
eClass 6.1 32160702
eClass 9.0 42030590
Quantity options
InVivoMAb anti m CD90, anti m Thy-1
Produkt Info
Concentration is determined using an extinction coefficient equal to 1.33 Endotoxin level is determined using an LAL gel clotting test Purity determined by SDS-PAGE
<2.0 EU/mg
PBS, pH 6.5
0.2 um filtration
Protein G
Recommended Isotipe Control/Prduct
Recommended Isotipe Control/Catalog#
The product should be stored undiluted at 4C, and protected from prolonged exposure to light. Do not freeze.
Tissue culture
Rat IgG2b
Pathogen Test Result: Murine Pneumonia Virus
Pathogen Test Result: Mouse Hepatitis Virus
Pathogen Test Result: Mouse Minute Virus
Pathogen Test Result: Mouse Parvovirus
Pathogen Test Result: Sendai Virus
Pathogen Test Result: Murine Encephalomyelitis
m CD90, m Thy-1
Becher, B., et al. (2014). "High-dimensional analysis of the murine myeloid cell system." Nat Immunol 15(12): 1181-1189. PubMed

Advances in cell-fate mapping have revealed the complexity in phenotype, ontogeny and tissue distribution of the mammalian myeloid system. To capture this phenotypic diversity, we developed a 38-antibody panel for mass cytometry and used dimensionality reduction with machine learning-aided cluster analysis to build a composite of murine (mouse) myeloid cells in the steady state across lymphoid and nonlymphoid tissues. In addition to identifying all previously described myeloid populations, higher-order analysis allowed objective delineation of otherwise ambiguous subsets, including monocyte-macrophage intermediates and an array of granulocyte variants. Using mice that cannot sense granulocyte macrophage-colony stimulating factor GM-CSF (Csf2rb(-/-)), which have discrete alterations in myeloid development, we confirmed differences in barrier tissue dendritic cells, lung macrophages and eosinophils. The methodology further identified variations in the monocyte and innate lymphoid cell compartment that were unexpected, which confirmed that this approach is a powerful tool for unambiguous and unbiased characterization of the myeloid system.

Campbell, K. J., et al. (2012). "Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection." Cell Death Differ 19(12): 1962-1971. PubMed

T cells developing in the thymus undergo rigorous positive and negative selection to ensure that those exported to peripheral lymphoid organs bear T-cell receptors (TCRs) capable of reacting with foreign antigens but tolerant of self. At each checkpoint, whether a thymocyte survives or dies is determined by antiapoptotic and proapoptotic Bcl-2 family members. We used Mcl-1 transgenic (tg) mice to investigate the impact of elevated expression of antiapoptotic Mcl-1 on thymocyte apoptosis and selection, making a side-by-side comparison with thymocytes from BCL-2tg mice. Mcl-1 was as effective as Bcl-2 at protecting thymocytes against spontaneous cell death, diverse cytotoxic insults and TCR-CD3 stimulation-driven apoptosis. In three different TCR tg models, Mcl-1 markedly enhanced positive selection of thymocytes, as did Bcl-2. In H-Y TCR tg mice, elevated Mcl-1 and Bcl-2 were equally effective at inhibiting deletion of autoreactive thymocytes. However, in the OT-1tg model where deletion is mediated by a peripheral antigen whose expression is regulated by Aire, Mcl-1 was less effective than Bcl-2. Thus, the capacity of Mcl-1 overexpression to inhibit apoptosis triggered by TCR stimulation apparently depends on the thymocyte subset subject to deletion, presumably due to differences in the profiles of proapoptotic Bcl-2 family members mediating the deletion.

Fischer, M. A., et al. (2011). "CD11b(+), Ly6G(+) cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection." PLoS Pathog 7(11): e1002374. PubMed

The goal of the innate immune system is containment of a pathogen at the site of infection prior to the initiation of an effective adaptive immune response. However, effector mechanisms must be kept in check to combat the pathogen while simultaneously limiting undesirable destruction of tissue resulting from these actions. Here we demonstrate that innate immune effector cells contain a peripheral poxvirus infection, preventing systemic spread of the virus. These innate immune effector cells are comprised primarily of CD11b(+)Ly6C(+)Ly6G(-) monocytes that accumulate initially at the site of infection, and are then supplemented and eventually replaced by CD11b(+)Ly6C(+)Ly6G(+) cells. The phenotype of the CD11b(+)Ly6C(+)Ly6G(+) cells resembles neutrophils, but the infiltration of neutrophils typically occurs prior to, rather than following, accumulation of monocytes. Indeed, it appears that the CD11b(+)Ly6C(+)Ly6G(+) cells that infiltrated the site of VACV infection in the ear are phenotypically distinct from the classical description of both neutrophils and monocyte/macrophages. We found that CD11b(+)Ly6C(+)Ly6G(+) cells produce Type I interferons and large quantities of reactive oxygen species. We also observed that depletion of Ly6G(+) cells results in a dramatic increase in tissue damage at the site of infection. Tissue damage is also increased in the absence of reactive oxygen species, although reactive oxygen species are typically thought to be damaging to tissue rather than protective. These data indicate the existence of a specialized population of CD11b(+)Ly6C(+)Ly6G(+) cells that infiltrates a site of virus infection late and protects the infected tissue from immune-mediated damage via production of reactive oxygen species. Regulation of the action of this population of cells may provide an intervention to prevent innate immune-mediated tissue destruction.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt und Sicherheitsdatenblatt) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Menge: 50mg
Lieferbar: In stock
Listenpreis: 2.300,10 €
Preis: 2.300,10 €


Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?